Blood Pressure Drugs Might Fight Diabetic Retinopathy

powered by healthline

Average Ratings

Study in mice reports success against proteins linked to the disease

FRIDAY, Jan. 8 (HealthDay News) -- New research in mice suggests that some drugs used to treat high blood pressure might help prevent and treat a disorder that causes people with diabetes to lose their vision.

The researchers tested candesartan (Atacand), a drug known as an angiotensin receptor blocker, on mice to see what would happen to 65 proteins in the retina that appear to be linked to diabetes. They found that the drug prevented more than 70 percent of the proteins from having abnormal changes.

The findings, which come in the largest study of its kind, could spell hope for people who suffer from diabetic retinopathy or are at risk for it. The disorder damages blood vessels in the retina. Previous research had suggested that high-blood pressure drugs -- also including ACE inhibitors -- might help.

The study findings were published in the Journal of Proteome Research.

More information

The U.S. National Eye Institute has more on diabetic eye disease.


-- Randy Dotinga
Copyright © 2010 ScoutNews, LLC. All rights reserved.
Article from
Top of page
General Drug Tools
General Drug Tools view all tools
Tools for
Healthy Living
Tools for Healthy Living view all tools
Search Tools
Search Tools view all tools
Insurance Plan Tools
Insurance Plan Tools view all tools

What is a reference number?

When you register on this site, you are assigned a reference number. This number contains your profile information and helps UnitedHealthcare identify you when you come back to the site.

If you searched for a plan on this site in a previous session, you might already have a reference number. This number will contain any information you saved about plans and prescription drugs. To use that reference number, click on the "Change or view saved information" link below.

You can retrieve information from previous visits to this site, such as saved drug lists and Plan Selector information.